Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab

• Published in: Journal of headache and pain Vol. 26; no. 1; pp. 26 - 12
• Main Authors: Diener, Hans-Christoph, Day, Kathleen A., Lipsius, Sarah, Aurora, Sheena K., Hindiyeh, Nada A., Detke, Holland C.
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 03.02.2025; Springer Nature B.V; BMC
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacology; Calcitonin; Calcitonin gene-related peptide; Chronic Disease; Chronic migraine; Disease prevention; Double-Blind Method; Episodic migraine; Female; Galcanezumab; Headache; Headaches; Humans; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Migraine; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Migraine prevention; Monoclonal antibodies; Neurology; Pain Medicine; Placebos; Young Adult; Chronic migraine; Calcitonin gene-related peptide; Galcanezumab; Episodic migraine; Migraine prevention

Background Chronic migraine (CM) is a highly disabling form of migraine in which patients have ≥ 15 headache days per month, of which at least 8 have the features of migraine. Galcanezumab is a monoclonal antibody to calcitonin gene-related peptide which is approved for the preventive treatment of m...